ascopubs.org

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial.

Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial. This is an ASCO Meeting Abstract ...
The Bakersfield Californian

SynergenX Opens Testosterone Cypionate Therapy to Female Patients

SynergenX, national leader in customized hormone optimization, prescription weight loss, and medically supervised wellness, is expanding its hormone replacement therapy (HRT) services for women to ...
ascopubs.org

Extreme bipolar androgen therapy: Alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial/LACOG ...

CUPID (64Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...